Bicara Therapeutics
Oncology Therapeutics · Biologics & Biosimilars
1open role
$269kmedian advertised pay
50+people
19stories in the press
Jobs
$242k – $289k per year · Remote (United States) · Full-Time · 5+ years exp · PhD
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$269k
Typical range
$202k – $331k
Open positions
5
5
Jobs
Senior
40%
Staff
20%
Architect
40%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 2 | $246k | $202k – $289k |
| Staff | 1 | $331k | $331k |
| Architect | 2 | $253k | $236k – $269k |
Highest paying role
Senior Director, Brand Lead - US
$331k
Normalized to USD per year
All salaries at Bicara Therapeutics
By role, level and city, against the market · 5 jobs with pay
Growth
Hiring Momentum
24/100
Hiring freeze
Open positions
5
0 opened / 4 closed in 30 days
Median time-to-fill
56 days
faster than 24% of the market
ATS activity
Every ~4 hours
11/08/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
30% ▲
Legal
20% ▼
Biotech
20% ▼
Finance
10% ▼
Sales
10% ▼
Operations
10% ▼
Tech stack
Technologies named in job postings at Bicara Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
3
Postings analysed
4
Stack modernity
43/100
Cloud & platforms
GCP
Developer tools
Microsoft Excel
Mandiant capa
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Premji InvestVia a fund
Aisling CapitalVia a fund
Foresite CapitalVia a fund
Omega FundsVia a fund
F-Prime CapitalVia a fund
194 portfolio companies: AblePay Health, Arboretum LifeSciences, Inc., Arexera Therapeutics and 191 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to brin...
Read more
Report
Bicara TherapeuticsAnnounces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August
Read more
Report
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Read more
Report
ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
The post ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squ
Read more
Report
ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
The post ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/
Read more
Report
ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab
The post ASCO 2026 Poster Presentation: Sustained depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from expansion cohorts of a phase 1/1b st
Read more
Report
Journal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trial
The post Journal of Clinical Oncology: Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase 1/1b Trial appeared first on Bicara Therapeutics.
Read more
Report
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
This Boston biotech focused on bifunctional cancer therapies reported a notable insider sale amid strong one-year stock gains.
Read more
Report
Report
MHNCS 2026 Oral Presentation: Ficerafusp alfa (2000mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma
The post MHNCS 2026 Oral Presentation: Ficerafusp alfa (2000mg Q2W) and pembrolizumab in HPV-negative first-line recurrent/metastatic head and neck squamous cell carcinoma appeared first on Bicara Therapeutics.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Boston
Boston
United States
Sales office
4 open roles 6 posted in 90 days 50-200 est. staff $260k Avg Salary
hires for Marketing, Finance, Field & Service